News - Page 4

The agreement will see Phlow as the first drugmaker to produce epinephrine injection API in the U.S., while Fresenius will work on formulation and finished doses to ship to U.S. hospitals and

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs.

Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion)

Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardena’s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).

Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site it’s shuttering in Franklin, Massachusetts, which currently employs about 200 people.

The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia’s total funding over the past year

China’s National Medical Products Administration suspended the import, sale and use of Sun’s rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.

Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.